- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Coherus BioSciences Inc (CHRS)
Coherus BioSciences Inc stock price live, this page displays NASDAQ CHRS stock exchange data. View the CHRS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Coherus BioSciences Inc real time stock price chart below.
What Is the Coherus BioSciences Inc Stock Price Today?
The Coherus BioSciences Inc stock price today is 1.605.
What Is the Stock Symbol for Coherus BioSciences Inc?
The stock symbol for Coherus BioSciences Inc is "CHRS."
What Stock Exchange Does Coherus BioSciences Inc Trade On?
Coherus BioSciences Inc is listed and trades on the NASDAQ stock exchange.
Is Coherus BioSciences Inc a Good Stock to Buy?
Determining whether Coherus BioSciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CHRS quote. (ISIN: US19249H1032)
What Is the Coherus BioSciences Inc Stock Price Today?
The Coherus BioSciences Inc stock price today is 1.605.
What Is the Stock Symbol for Coherus BioSciences Inc?
The stock symbol for Coherus BioSciences Inc is "CHRS."
What Stock Exchange Does Coherus BioSciences Inc Trade On?
Coherus BioSciences Inc is listed and trades on the NASDAQ stock exchange.
Is Coherus BioSciences Inc a Good Stock to Buy?
Determining whether Coherus BioSciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CHRS quote. (ISIN: US19249H1032)
1.605
-0.025(-1.53%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.580
1.675
52 wk Range
0.710
2.616
CHRS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.5801.675
52 wk Range
0.7102.616
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CHRS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
6.750
Upside
+320.56%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
- Charming Shoppes receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Charming Shoppes receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Coherus BioSciences Inc SWOT Analysis
Oncology Pivot | Coherus BioSciences transitions from biosimilars to immuno-oncology, facing challenges and opportunities in its strategic transformation |
Casdozo's Promise | Explore the potential of casdozo, Coherus's anti-IL-27 antibody, showing encouraging results in liver cancer treatment and driving pipeline advancement |
Financial Tightrope | Delve into Coherus's complex financial landscape, balancing debt obligations and cash burn against the need to fund ongoing research and development |
Market Dynamics | Analysts set price targets ranging from $1.50 to $7.00, reflecting varied perspectives on Coherus's ability to navigate competitive pressures and pipeline potential |
Coherus BioSciences Inc Earnings Call Summary for Q3/2025
- Coherus BioSciences reported Q3 2025 revenue of $11.6M (13.17% below forecast) with EPS of -$0.33, triggering a 4.79% stock decline to $1.49
- LOQTORZI net revenue increased 92% year-over-year, while the company streamlined operations by reducing headcount and divesting its biosimilar business
- R&D expenses rose 24% to $27.3M while SG&A costs decreased 11% to $24.9M, reflecting the company's strategic shift toward innovative oncology
- Management forecasts revenue growth to $16.1M in Q4 2025 and $22.5M by Q3 2026, with plans to expand sales force by 15% and launch digital education programs
- Multiple clinical data readouts are anticipated in 2026, with executives emphasizing the company's focus on 'achieving a step change in patient survival'
Last Updated: 2025-11-06, 07:02 p/m
Read Full TranscriptCompare CHRS to Peers and Sector
Metrics to compare | CHRS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCHRSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.3x | −2.6x | −0.4x | |
PEG Ratio | 0.00 | 0.01 | 0.00 | |
Price/Book | 3.9x | 1.9x | 2.6x | |
Price / LTM Sales | 5.7x | 1.9x | 3.1x | |
Upside (Analyst Target) | 298.8% | 144.1% | 58.2% | |
Fair Value Upside | Unlock | 9.2% | 8.5% | Unlock |
Analyst Ratings
5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 6.750
(+320.56% Upside)
Earnings
Latest Release
Mar 09, 2026
EPS / Forecast
-0.34 / -0.34
Revenue / Forecast
12.7M / 14.16M
People Also Watch
FAQ
What Is the Coherus BioSciences (CHRS) Stock Price Today?
The Coherus BioSciences stock price today is 1.605 USD.
What Stock Exchange Does Coherus BioSciences Trade On?
Coherus BioSciences is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Coherus BioSciences?
The stock symbol for Coherus BioSciences is "CHRS."
What Is the Coherus BioSciences Market Cap?
As of today, Coherus BioSciences market cap is 237.580M USD.
What Is Coherus BioSciences's Earnings Per Share (TTM)?
The Coherus BioSciences EPS (TTM) is -1.563.
When Is the Next Coherus BioSciences Earnings Date?
Coherus BioSciences will release its next earnings report on Apr 30, 2026.
From a Technical Analysis Perspective, Is CHRS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Coherus BioSciences Stock Split?
Coherus BioSciences has split 0 times.
How Many Employees Does Coherus BioSciences Have?
Coherus BioSciences has 147 employees.
What is the current trading status of Coherus BioSciences (CHRS)?
As of Mar 30, 2026, Coherus BioSciences (CHRS) is trading at a price of 1.605 USD, with a previous close of 1.630 USD. The stock has fluctuated within a day range of 1.580 USD to 1.675 USD, while its 52-week range spans from 0.710 USD to 2.616 USD.
What Is Coherus BioSciences (CHRS) Price Target According to Analysts?
The average 12-month price target for Coherus BioSciences is 6.750 USD, with a high estimate of 10 USD and a low estimate of 4 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +320.56% Upside potential.
What Is the CHRS Premarket Price?
CHRS's last pre-market stock price is 1.640 USD. The pre-market share volume is 490.000, and the stock has decreased by 0.010, or 0.610%.
What Is the CHRS After Hours Price?
CHRS's last after hours stock price is 1.694 USD, the stock has decreased by 0.064, or 3.930%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.